Tocilizumab (Acterma) is an immunosuppressive drug (IL-6 inhibitor) mainly used in the treatment of rheumatoid arthritis and is currently being tested in COVID-19 patients. Explore the live graph.
Mechanistic analysis of Tocilizumab
VEGFA
Possibly implicated genes in SARS-CoV-2-mediated blood vessel disease
In addition to respiratory symptoms, novel findings have shown vascular complications in a series of patients with COVID-19, suggesting that COVID-19 is more to a respiratory infection caused by SARS-CoV-2. This graph illustrates some of the possible mechanisms (genes) by which these effects of SARS-CoV-2 may be mediated. Explore the live graph.